194 related articles for article (PubMed ID: 11886400)
21. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
Shenkman B; Einav Y
Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304
[TBL] [Abstract][Full Text] [Related]
22. Von Willebrand factor--cleaving protease activity in congenital thrombotic thrombocytopenic purpura.
Allford SL; Harrison P; Lawrie AS; Liesner R; MacKie IJ; Machin SJ
Br J Haematol; 2000 Dec; 111(4):1215-22. PubMed ID: 11167764
[TBL] [Abstract][Full Text] [Related]
23. Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura.
Snider CE; Moore JC; Warkentin TE; Finch CN; Hayward CP; Kelton JG
Am J Hematol; 2004 Dec; 77(4):387-90. PubMed ID: 15551280
[TBL] [Abstract][Full Text] [Related]
24. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.
Peyvandi F; Ferrari S; Lavoretano S; Canciani MT; Mannucci PM
Br J Haematol; 2004 Nov; 127(4):433-9. PubMed ID: 15521921
[TBL] [Abstract][Full Text] [Related]
25. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.
Lattuada A; Rossi E; Calzarossa C; Candolfi R; Mannucci PM
Haematologica; 2003 Sep; 88(9):1029-34. PubMed ID: 12969811
[TBL] [Abstract][Full Text] [Related]
26. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
[TBL] [Abstract][Full Text] [Related]
27. ADAMTS13 and TTP.
Zheng X; Majerus EM; Sadler JE
Curr Opin Hematol; 2002 Sep; 9(5):389-94. PubMed ID: 12172456
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for thrombotic thrombocytopenic purpura.
Cataland SR; Wu HM
Curr Opin Hematol; 2005 Sep; 12(5):359-63. PubMed ID: 16093780
[TBL] [Abstract][Full Text] [Related]
30. Thrombotic thrombocytopenic purpura: from platelet aggregates to plasma.
Marques MB; Mayfield CA; Blackall DP
Am J Clin Pathol; 2004 Jun; 121 Suppl():S89-96. PubMed ID: 15298154
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
Tsai HM; Li A; Rock G
Clin Lab; 2001; 47(7-8):387-92. PubMed ID: 11499801
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features and laboratory findings of thrombotic thrombocytopenic purpura associated with ticlopidine].
Yagi H
Rinsho Byori; 2005 Jul; 53(7):630-8. PubMed ID: 16104532
[TBL] [Abstract][Full Text] [Related]
33. [From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene].
Schiphorst RH; van de Kar NC; van den Heuvel LP
Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2422-4. PubMed ID: 14694551
[TBL] [Abstract][Full Text] [Related]
34. Simple plasma exchange reduced autoantibody to von Willebrand factor-cleaving protease in a Japanese man with ticlopidine-associated thrombotic thrombocytopenic purpura.
Orimo S; Ozawa E; Yagi H; Ishizashi H; Matsumoto M; Fujimura Y
J Intern Med; 2002 Mar; 251(3):280-1. PubMed ID: 11886490
[No Abstract] [Full Text] [Related]
35. [Measurement of plasma von Willebrand factor cleaving protease in patients with varied thrombotic microangiopathy].
Katagiri H; Kawai Y; Sugizaki N; Sakai K; Handa M; Okamoto S; Watanabe K
Rinsho Byori; 2003 Jun; 51(6):516-21. PubMed ID: 12884737
[TBL] [Abstract][Full Text] [Related]
36. [The role of von Willebrand protease in aetiopathogenesis of thrombotic thrombocytopenic purpura].
Suvajdzić-Vuković N
Srp Arh Celok Lek; 2007; 135(5-6):360-6. PubMed ID: 17633329
[TBL] [Abstract][Full Text] [Related]
37. Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection.
Franchini M
Med Hypotheses; 2005; 65(6):1128-31. PubMed ID: 16084670
[TBL] [Abstract][Full Text] [Related]
38. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.
Rieger M; Mannucci PM; Kremer Hovinga JA; Herzog A; Gerstenbauer G; Konetschny C; Zimmermann K; Scharrer I; Peyvandi F; Galbusera M; Remuzzi G; Böhm M; Plaimauer B; Lämmle B; Scheiflinger F
Blood; 2005 Aug; 106(4):1262-7. PubMed ID: 15890682
[TBL] [Abstract][Full Text] [Related]
39. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
Thomas MR; de Groot R; Scully MA; Crawley JT
EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
[TBL] [Abstract][Full Text] [Related]
40. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura.
Luken BM; Turenhout EA; Hulstein JJ; Van Mourik JA; Fijnheer R; Voorberg J
Thromb Haemost; 2005 Feb; 93(2):267-74. PubMed ID: 15711742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
